GLP-1 Drugs Shift from Medical Treatment to Lifestyle Enhancement for Affluent Consumers

Blockbuster GLP-1 medications, originally developed to treat diabetes and obesity, are increasingly being marketed as lifestyle drugs for weight management in people without medical conditions. This shift reflects a growing trend where pharmaceutical companies reposition these medications from treating patients with chronic diseases to targeting affluent consumers seeking cosmetic weight loss. The change raises questions about equitable access, medical necessity, and the commercialization of healthcare, as wealthy individuals gain easier access to these in-demand drugs while patients with diabetes and obesity face shortages and affordability challenges.